What They're Not Telling You About AMD
AMD closed Friday at a record $455, propelled by a Q1 revenue beat of $10.25 billion, including $5.8 billion from data‑center sales. CEO Lisa Su forecast $11.2 billion next quarter and a 35% compound revenue growth for the next three‑to‑five years, citing AI demand. The rally is underpinned by multi‑year GPU contracts with OpenAI and Meta, each backed by $1.6 million worth of one‑cent stock warrants that could dilute roughly 20% of the company. While the deals lift AMD’s top line, the equity component and reliance on a handful of hyperscalers add valuation and execution risk.
The $1 Trillion Cardiovascular Reset
The blog highlights Eli Lilly's $1.3 billion acquisition of Verve Therapeutics, targeting a one‑shot PCSK9 gene‑editing therapy that could replace daily statins. It underscores the massive adherence problem—up to 75% of statin users stop within two years—and the untapped 1.4 billion‑person market for...
The $3 Trillion Quarter
In early 2026 a consortium of 21 banks is preparing a historic IPO for SpaceX, targeting a $1.75 trillion valuation and a $75 billion raise—2.5 times the size of Saudi Aramco’s record offering. Anthropic and OpenAI are slated to follow, together adding roughly...
Macro Notes Predictions — Issue #1 · Q2 2026
The author launches a quarterly macro outlook that scores each prediction for transparency, beginning with 12 bets ranging from aggressive AI‑hyperscaler corrections to defensive private‑credit risks. Key data points include $715 billion AI hyperscaler capex, uranium spot prices above $100 per...
Why Ports Became the Strategic Asset of the Decade
On March 4 2025 CK Hutchison announced the sale of 80% of its global port portfolio to a Western consortium led by BlackRock, MSC and Global Infrastructure Partners for $22.8 billion. The transaction covers 43 ports in 23 countries, including the Panama Canal...
The Pharma Sovereignty Playbook: How I’m Playing the $1.5 Trillion Drug Supply Crisis
A 2023 FDA inspection of Intas Pharmaceuticals’ plant in India halted half of the U.S. cisplatin supply, triggering nationwide shortages of both cisplatin and its substitute carboplatin. The crisis highlighted that only 24% of active pharmaceutical ingredient (API) manufacturing for...
The 17-Year Orderbook Nobody’s Tracking — Inside Shipbuilding’s Quiet Supercycle
A veteran LNG shipping CEO warned in December 2025 that the global orderbook of 234 new LNG carriers for 2026‑2030 will fall far short of the 229 million tons of liquefaction capacity slated for completion by 2030, creating a 70 Mt shortfall....
The War Premium — Defense, Insurance, and the New Cost of Global Trade
In February 2026 the U.S. and Israel’s airstrikes on Iran triggered a rapid collapse of traffic through the Strait of Hormuz, not by missiles but by a spike in war‑risk insurance premiums. Premiums surged from under 0.25% to 5% of...
The $100 Trillion Energy Crisis Nobody Saw Coming
The Strait of Hormuz shut completely after Iran’s retaliation, halting all commercial traffic and stranding nearly a fifth of the global tanker fleet. While crude oil found temporary relief through Saudi and UAE pipelines and strategic reserves, other energy streams—LNG,...